U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07375693) titled 'Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients' on Dec. 10, 2025.
Brief Summary: In Bangladesh Melatonin is currently used for insomnia. Its potential therapeutic benefits beyond sleep regulation. This study aimss to evaluate the effects of melatonin supplementation on oxidative stress markers, neuroinflammation and clinical outcomes in patients with Parkinson's disease. The main question it aims to answer:
In patients with Parkinson's disease receiving levodopa, does melatonin supplementation, compared to levodopa treatment alone, improve the symptoms of PD over a 12 week of per...